CME/CE LIBRARY

Throughout this section, you will find information that is helpful if you are a physician, nurse or allied health care professional.

We are working to continually engage our network, by creating information to help professionals find resources about PF and provide access to up-to-date information. Continuing medical education consists of educational activities and opportunities which serve to maintain, develop, or increase the knowledge, skills, professional performance, and relationships that a physician, nurse or allied health care professional uses to provide services for patients, the public, or the profession.

CME/CE OBJECTIVES

Empowering CME

















Empowering the IPF Patient through Shared Decision Making, Multidisciplinary Care, and Treatment Awareness
1.00 AMA  PRA Category 1 Credits
Release Date: December 20, 2018
Expiration Date: December 20, 2019


Learning Objectives
  • Outline needs and concerns of IPF patients over the disease course
  • Discuss guideline recommendations for differentiating IPF from other interstitial lung diseases to ensure a definitive diagnosis
  • Interpret the efficacy and safety data for pharmacotherapies used to treat IPF
  • Formulate comprehensive management plans, including pharmacologic and nonpharmacologic approaches and support strategies
  • Engage patients and their families in shared decision making for the management of IPF
  • Describe the benefits and roles of multidisciplinary team over the course of IPF
Peer View logo











Examining the IPF Patient's Journey to Diagnosis, Appropriate Therapy, and Overall Individualized Care
0.75 AMA  PRA Category 1 Credits
Release Date: November 20, 2018
Expiration Date: November 19, 2019

Learning Objectives:

  • Employ evidence-based strategies to accurately diagnose IPF
  • Design patient-centered IPF management plans based on shared decision-making and evidence-based recommendations for therapy
  • Apply effective communication strategies to provide adequate disease- and treatment-related education and guidance to patients with IPF
CME Reframing Palliative Care







                                     
Reframing Palliative Care to Patients with IPF
1.25 AMA PRA Category 1 Credits
Release Date: August 2, 2018
Expiration Date: August 2, 2019

Learning Objectives:
  • Recognize the barriers that prevent the timely and effective use of palliative care for patients with long-term progressive diseases, such as IPF.
  • Develop strategies for early communication and implementation of an effective plan for supportive care.














Every Minute & Every Breath Counts: Stepping up Efforts in Idiopathic
Pulmonary Fibrosis

1.0 AMA PRA Category 1 Credits™
Release Date: September 7, 2018
Expiration Date: September 6, 2019

Learning Objectives:
  • Implement guideline-directed referrals to specialty centers and enhance care coordination strategies to ensure timely diagnosis and treatment initiation in patients with IPF.
  • Apply patient-reported outcomes and evidence on the efficacy and safety of antifibrotic therapies to shared decision-making with IPF patients and caregivers
  • Support IPF patients and caregivers in self-management, including access and adherence to supportive treatments and antifibrotic therapy












Effective Clinician-Patient Partnering in IPF
0.50 AMA PRA Category 1 Credits™
Release Date: February 2018
Expiration Date: February 28, 2019

Learning Objectives:

  • Demonstrate communication techniques for use with IPF patients that include effective disease-state education.
  • Describe the relationship between delayed referral of patients with IPF to tertiary care and reduced survival.
  • Identify the degree of impact of IPF on patients’ quality of life.




What IPF Really Means: Discussions With Caregivers, Patients, and Healthcare Providers at PFF Summit 2017
Topics covered in this activity are diagnosis, therapeutic advances, IPF support groups, and advice for patients and physicians
















Key Takeaways From the IPF Experts at the PFF Summit 2017
1.0 AMA PRA Category 1 Credits™
Release Date: December 20, 2017
Expiration Date: December 20, 2018

Learning Objectives:

  • Describe recent advances in the genetics of pulmonary fibrosis pathogenesis and how they can be applied to improved patient care.
  • Review clinical trial data supporting the efficacy and safety of pirfenidone and nintedanib.
  • Explain the potential role of senolytic drugs in the management of IPF.
  • Discuss emerging resources available for managing IPF, including the Clinical Care Network and the patient registry.



Beyond the Guidelines Promising Practices to Improve the Care of Patients 
With Pulmonary Fibrosis

1.0 AMA PRA Category 1 Credits™












Integrating Updated Guidelines for Treatment of Idiopathic Pulmonary
Fibrosis into Clinical Practice

0.50 AMA PRA Category 1 Credit(s)™
Release Date: December 2017
Expiration Date: December 31, 2018

Learning Objectives:

  • Discuss key changes in current guidelines for treatment of idiopathic pulmonary fibrosis (IPF).
  • Design a therapeutic strategy for IPF incorporating current drug treatment recommendations.
  • Develop evidence-based approaches for managing common comorbidities of IPF and adverse events associated with its treatment.















Practice Self-Assessment for Diagnosis and Management of Idiopathic
Pulmonary Fibrosis (IPF)

0.5 AMA PRA Category 1 Credit(s)™
Release Date: June 2017
Expiration Date: June 30, 2018       

Learning Objectives:
  • Demonstrate an understanding of the signs, symptoms, and epidemiology of IPF to better recognize patients in need of specialty care.
  • Describe the benefits of multidisciplinary care for IPF and the reasons for these benefits.
  • Engage a multidisciplinary care team to treat patients with IPF, by referral or collaboration. 
  • Describe the relationship between delayed referral of patients with IPF to tertiary care and potential reduced survival.














A Current Practice Snapshot of IPF Diagnosis and Management
Release Date: December 1, 2016
Expiration Date: December 31, 2017

Learning Objectives:
  • Utilize the signs, symptoms, and epidemiology of IPF to better recognize patients in need of specialty care.
  • Employ a multidisciplinary care team approach for IPF to enhance patient outcomes.
  • Provide timely referral of patients with IPF to tertiary care to improve survival.
  • Review clinical trial data supporting the efficacy and safety of pirfenidone and nintedanib.
  • Select appropriate pharmacologic therapy for patients with IPF.
  • Communicate with patients with IPF and provide effective disease state education.













Pulmonology Case Challenge
Release Date: July 2016
Expiration Date: July 31, 2017

Learning Objectives
  • Utilize the signs, symptoms, and epidemiology of certain interstitial lung diseases (ILD) to better recognize patients in need of specialty care.
  • Employ a multidisciplinary care team approach for ILD to enhance patient outcomes.
  • Provide timely referral of patients with ILD to tertiary care to improve survival.
  • Review clinical trial data supporting the efficacy and safety of pirfenidone and nintedanib.
  • Select appropriate pharmacologic therapy for patients with ILD.
  • Communicate with patients with ILD and provide effective disease state education.














Clinical Decision Making in (IPF) Management
Release Date: July 2016
Expiration Date: July 31, 2017

Learning Objectives
  • Utilize the signs, symptoms, and epidemiology of IPF to better recognize patients in need of specialty care.
  • Employ a multidisciplinary care team approach for IPF to enhance patient outcomes.
  • Provide timely referral of patients with IPF to tertiary care to improve survival.
  • Review clinical trial data supporting the efficacy and safety of pirfenidone and nintedanib.
  • Select appropriate pharmacologic therapy for patients with IPF.
  • Communicate with IPF patients and provide effective disease state education.











PFF Summit 2015: Key Takeaways in IPF Disease Management and Effective
Clinician-Patient Partnering

Release Date: May 2016
Expiration Date: April 30, 2017

Learning Objectives:
  • Employ a multidisciplinary care team approach for IPF to enhance patient outcomes.
  • Review clinical trial data supporting the efficacy and safety of pirfenidone and nintedanib.
  • Select appropriate pharmacologic therapy for patients with IPF.
  • Communicate with patients with IPF and provide effective disease-state education.

TO OBTAIN CME/CEU CREDIT FOR PFF SUMMIT 2017, CLICK HERE

How to Obtain Credit

Please go online to CME University at: www.cmeuniversity.com and register or login (takes less than 1 minute).

Once logged into CME University, follow these steps:
1. Click on the “Find Post-Test/Evaluation by Course:” at the top of the page.
2. Type in “12206” and hit enter.
3. Click on the Activity Title.
4. Choose your profession/type of credit you are seeking.
5. Complete the online Evaluation Form.
Upon completion of the online Evaluation form, you will have immediate access to a certificate of attendance to print or save for your files.
 
If you have any questions regarding the CME/CE certification for this activity, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.
 
For Pharmacists and Respiratory Therapists – the evaluation must be completed online within 30 days of the activity.

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >